2016 TAG Update
TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Reconsideration of support for impending 21st Century Cures Act
Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.
TAGline Fall 2016
Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.
Rallying the Multitude to Free the (Generic) HCV Cure
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South By Bryn Gay We can now cure the hepatitis C virus (HCV) with a coformulation of drugs that yields sustained virologic responses for all…
Decriminalization is a Public Health Strategy
We can’t end the viral hepatitis epidemics unless we end the war on drug users By Annette Gaudino “Unidentified Filipino male. Unidentified Filipino male. Unidentified Filipino female. Unidentified Filipino male…” It takes a long time to read 1,900 names, long…
Letter to Hillary Clinton on HCV Drug Prices
Dear Secretary Clinton, As a national group of healthcare providers, advocates, and patients dedicated to preventing and treating viral hepatitis, we welcome your recent comments in Cleveland regarding the high price of pharmaceutical drugs to cure the hepatitis C virus (HCV). We are encouraged by the broad support for government action on the high price of pharmaceutical drugs, especially those for viral hepatitis, and to see this issue being directly addressed by elected officials at all levels of government. However, we are writing you today out of concern that your current healthcare platform does not specifically or adequately address the national and international viral hepatitis epidemics. We must work together to raise the profile of hepatitis B and C as urgent public health priorities.
Epclusa Fact Sheet
Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older.
WORLD HEPATITIS DAY 2016 Direct-Acting (Antiviral) Generics Work: Free the cure!
To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org.
Treatment Action Group Welcomes Hepatitis C Virus (HCV) Project Co-Directors Annette Gaudino and Bryn Gay
Today Treatment Action Group (TAG) welcomes incoming Hepatitis C Virus (HCV) Project Co-Directors Annette Gaudino and Bryn Gay. Annette begins at TAG today and Bryn on June 20.
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.